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Background: To describe the spectral domain optical coherence tomography (SD-OCT) findings of a patient who
developed pigmentary retinopathy following high-dose deferoxamine administration.
Case presentation: A 34-year-old man with thalassemia major complained of nyctalopia and decreased vision
following high-dose intravenous deferoxamine to treat systemic iron overload. Fundus examination revealed
multiple discrete hypo-pigmented lesions at the posterior pole and mid-peripheral retina. Recovery was partial
following cessation of desferrioxamine six weeks later. A follow-up SD-OCT showed multiple accumulated
hyper-reflective deposits primarily in the choroid, retina pigment epithelium (RPE), and inner segment and outer
segment (IS/OS) junction.
Conclusion: Deferoxamine retinopathy primarily targets the RPE–Bruch membrane–photoreceptor complex,
extending from the peri-fovea to the peripheral retina with foveola sparing. An SD-OCT examination can serve as a
simple, noninvasive tool for early detection and long-term follow-up.
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Deferoxamine is an iron-chelating agent used to treat
chronic iron overload in patients with thalassemia major
and other hematologic conditions requiring routine blood
transfusion [1,2]. The incidence of deferoxamine-related
ocular toxicity is approximately 1.2% based on a prior
study [3]. The clinical presentations may include night
blindness, centrocaecal scotoma, constricted peripheral vis-
ual field, pigmentary retinopathy, and optic neuropathy [3].
Retinal pigmentary change was most frequently reported
[4]. This case report pathologically characterizes the
spectral domain optical coherence tomography (SD-OCT,
SPECTRALIS SD-OCT, Heidelberg, Germany) and near-
infrared reflectance (NIR) findings in a patient with defer-
oxamine retinopathy.Case presentation
A 34-year-old Taiwanese man with beta-thalassemia major
had been administered routine blood transfusion and* Correspondence: yihsing@gmail.com
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since youth. He was hospitalized for a compression fracture
and myelopathy of the thoracic spine. He presented with
acute onset of decreased vision, impaired color vision, and
night blindness following continuous intravenous deferox-
amine (98 mg/kg) for 42 days for the treatment of elevated
serum ferritin level. On ophthalmic examinations, the best-
corrected vision was 20/200 in the right eye and 20/40 in
the left eye. The intraocular pressure measurement and an-
terior segment examination yielded normal results for both
eyes. The fundus examination revealed multiple discrete
hypo-pigmented circular lesions over the posterior pole
and mid-peripheral retina in both eyes.
Deferoxamine retinopathy was suspected, and the patient
was switched to oral deferasirox/deferiprone. Six weeks
later, there was an improvement in the best-corrected vi-
sion (20/60 in the right eye and 20/25 in the left eye) and
color vision. Retinal pigmentary changes became confluent
(Figure 1). NIR showed hyper-reflective deposits particu-
larly in the parafoveal and perifoveal areas (Figure 2). SD-
OCT showed multiple confluent hyper-reflective deposits
in the choroid, retinal pigment epithelium (RPE) and IS/OS
junction. Thickened RPE, Bruch’s membrane, and choroid
space were also discovered. The IS/OS junction was most. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Dilated fundus examination at the 6-week follow-up
visit. A dilated fundus examination revealed diffuse and confluent
hypo-pigmented pinpoint lesions extending from the posterior pole
(arrow) to the peripheral retina (arrowhead).
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Figure 3 SD-OCT at the 6-week re-examination. SD-OCT revealed
a disrupted IS/OS junction (arrow) and multiple diffuse and confluent
hyper-reflective deposits in the retinal pigment epithelium (RPE), IS/OS
junction, and choroid (arrowhead). Thickened RPE, Bruch’s membrane,
and choroidal space were also observed.
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than at the foveola area (Figure 3).
Conclusion
Deferoxamine is a widely used chelating agent in treating
transfusional hemochromatosis [1,5]. Visual symptoms in-
cluded decreased visual acuity, night blindness, and colour
vision abnormalities [2-6]. These ophthalmic examination
findings have been reported extensively. Sumu et al. ob-
served speckled hyper-fluorescence with well-demarcated
areas of blocked fluorescence on fluorescein angiography
[6]. Markedly reduced photopic, scotopic, and 30-Hz
flicker response amplitudes were reported on electrore-
tinograms. Electro-oculogram typically showed reduced
light-peak to dark-trough ratios [4,6]. Viola et al. reported
abnormal fundus autofluorescence in 9% of 197 patients,
but only 5 patients reported visual symptoms [7]. Viola
et al. further described the pattern dystrophy–like or min-
imal changes of macular lesions in patients with deferox-
amine retinopathy by using NIR and SD-OCT which
pointed out the disease itself affects the RPE–Bruch mem-
brane–photoreceptor complex [8].
The pathophysiology of deferoxamine-related retinop-
athy has been investigated for several years. Rahi et al. firstOD OS
Figure 2 Near-infrared reflectance (NIR) at the 6-week
re-examination. NIR showed hyper-reflective deposits particularly
in the parafoveal and perifoveal areas.reported electron microscopic findings of deferoxamine
retinopathy, including patchy RPE depigmentation, abnor-
mally thickened Bruch's membrane, and normal photore-
ceptors [9]. Previous studies also discovered that iron
overload and iron-chelating agents both may be mutually
confounding factors in the causation of ocular changes of
thalassemia such as RPE mottling [5,10-13]. The SD-OCT
findings in our case revealed multiple confluent hyper-
reflective deposits in the RPE, IS/OS junction and choroid
(Figure 3). We hypothesized that hyper-reflective deposits
detected by means of SD-OCT may represent a primarily
involvement of RPE–Bruch membrane–photoreceptor
complex in deferoxamine toxicity which correlated with
previous histologic findings [8,9].
Ocular deferoxamine toxicity could cause vision im-
pairment; regular ophthalmic assessment is required in
these patients. We presented the SD-OCT findings of de-
feroxamine retinopathy highly correlated with previous
histologic descriptions and showed that the toxicity pri-
marily involved the RPE–Bruch membrane–photoreceptor
complex. Noninvasive SD-OCTand NIR imaging, both well
tolerated by patients, may be helpful in early detection and
long-term monitoring.
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